EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Does ABPA Contribute to Bronchiectasis? A Structured Evaluation of Competing Hypotheses

Ritesh Agarwal iD, Inderpaul Singh Sehgal iD, Valliappan Muthu iD, Philip Bardin iD

Clinical & Experimental Allergy · 2026

DOI: 10.1111/cea.70299 ↗

At a glance

Übersichtsarbeit in Clinical & Experimental Allergy, 2026. Written by Ritesh Agarwal and 3 co-authors. Institution: Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Major MEDLINE topics: Bronchiectasis, Aspergillosis, Allergic Bronchopulmonary, Aspergillus fumigatus. Cited 1 times so far (Crossref); 51 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Whether allergic bronchopulmonary aspergillosis (ABPA) causes bronchiectasis or merely represents Aspergillus fumigatus colonisation of damaged airways remains debated. Establishing causality is challenging because airway damage is predominantly driven by host immune responses rather than by direct fungal invasion. We systematically evaluate four competing hypotheses: (i) ABPA causes bronchiectasis, (ii) reverse causation, with bronchiectasis predisposing to ABPA, (iii) a shared underlying factor independently producing both conditions and (iv) a spurious association. We evaluate radiological, pathological, immunological, temporal and therapeutic evidence in relation to these hypotheses. The characteristic radiological phenotype (central bronchiectasis and high‐attenuation mucus), eosinophil‐dominant histopathology and disease‐specific immunological profile (typically absent in other forms of bronchiectasis despite Aspergillus colonisation) distinguish ABPA from incidental colonisation. Randomised controlled trials demonstrating that antifungal treatment or anti‐inflammatory therapy (glucocorticoids and biological agents) improve clinical and immunological outcomes argue against a purely spurious association. Temporal observations indicate that ABPA precedes bronchiectasis in many cases. While uncertainty remains and host susceptibility is likely essential, the available evidence suggests that ABPA contributes to bronchiectasis through antigen‐driven immune injury, supporting the use of appropriate antifungal and immunomodulatory therapy in selected patients.

Subjects

MeSH terms (MEDLINE)

BronchiectasisAspergillosis, Allergic BronchopulmonaryAspergillus fumigatusHumansAntifungal AgentsDisease Susceptibility

Author keywords

Bradford Hill criteriaIgEIgGallergic bronchopulmonary mycosisallergyasthmacausalitycomputed tomography

Substances

Antifungal Agents

Authors and institutions

  • Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Monash Lung Sleep Allergy & Immunology, Monash University and Medical Centre, Melbourne, Australia.

ORCID profiles: Ritesh Agarwal, Inderpaul Singh Sehgal, Valliappan Muthu, Philip Bardin

Cite

APA

Agarwal, R., Sehgal, I. S., Muthu, V., & Bardin, P. (2026). Does ABPA Contribute to Bronchiectasis? A Structured Evaluation of Competing Hypotheses. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.70299

Vancouver

Agarwal R, Sehgal IS, Muthu V, Bardin P. Does ABPA Contribute to Bronchiectasis? A Structured Evaluation of Competing Hypotheses. Clinical & Experimental Allergy. 2026. doi:10.1111/cea.70299

BibTeX
@article{Agarwal2026,
  author = {Agarwal, Ritesh and Sehgal, Inderpaul Singh and Muthu, Valliappan and Bardin, Philip},
  title = {Does ABPA Contribute to Bronchiectasis? A Structured Evaluation of Competing Hypotheses},
  journal = {Clinical & Experimental Allergy},
  year = {2026},
  doi = {10.1111/cea.70299}
}
Start for free →